Tempus Labs and Eric Lefkofsky’s Fight Against Cancer

The disease cancer has been characterized as being a tricky antagonist that mimics the body’s normal functions so it can grow undisturbed. Because the body doesn’t recognize that there is a problem, it does not attack the cancer and it continues to grow unabated. Eric Lefkofsky is using Tempus Labs to devise successful ways to stop this complex disease.

Tempus Labs uses data to improve the way cancer patients are diagnosed and treated. The data is gathered from comprehensive cancer centers and top academic institutions. Eric Lefkofsky hopes to use Tempus to disseminate the cancer data to every doctor that has a cancer patient so that treatments can be design around each individual patient in a customized manner.

After the data garnered from the treatment of each cancer patient is stored in a central location it will be easier to disseminate the information to the important parties. The patients’ treatment data is stored in their medical records, but it has not been clinically coordinated for each type or cancer and most importantly, the information has not been accessible by physicians treating cancer patients.

Tempus was created to be central location for all this cancer treatment data. By bringing molecular data and clinical data together, Lefkofsky hopes Tempus will result in personalized, effective and more informative cancer treatments. Tempus is meant to contain data from every area of cancer treatments including molecular, therapeutic, clinical and the outcome response.

Molecular data is the patients’ DNA and RNA. RNA is the Ribonucleic acid, a polymeric molecule that is a part of various biological activities such as coding, decoding, regulation, and the work of genes. DNA is useful because it is considered to be an important element in developing personalized medicine for cancer patients.

The centralized location of such a vast amount of data will enable the fight for cancer to become more targeted and focused. Using big data analytics cancer treatments can be more effectively designed and administered. Currently, Tempus Labs can analyze data for 50,000 patients annually. Ultimately Tempus Labs will be able to take miscellaneous cancer treatment records and compile them in an orderly and annotated manner for ease of access. Lefkofsky’s Tempus will continue its use of clinical records, molecular data, DNA, RNA, etc. to compile a complete history of cancer treatments, their successes and failures to eventually supply all the necessary data needed to fight cancer successfully.

Eric Lefkofsky’s  Social Media: www.facebook.com/eplefkofsky/

Dr. David Samadi Explores How STDs May Trigger Cancerous Prostate Cells

Scientists are pretty sure that STDs boost the growth rate of cancerous prostate cells. According to urology expert, Dr. David Samadi, sexually active men must practice safe sex. Clinical studies reveal that ehe sexually transmitted disease, trichomonas vaginalis, trigger inflammatory reactions that could promote cancer growth.Another point of concern is that this particular STD is usually asymptomatic, and often goes unnoticed, but clinical studies confirm men with a Trichomonas infection are more than two times more likely to develop aggressive prostate cancer.

What Is Trichomonas Vaginalis?

Trichomonas vaginalis is a parasite . This means that the small organism uses humans as hosts , feeds on them, and colonizes them for reproduction. The pathogen lives anaerobically, not requiring an oxygenated environment for its growth. It’s one of the most common STDs in the world, and the trichomonads are found primarily under the foreskin, in the prostate or in the urethra. If no treatment is applied, the disease usually goes into a chronic phase. Although it is not a life-threatening disease, doctors have long associated it with ovarian cancer, and now research confirms how this infection makes men much more vulnerable to prostate cancer.Scientists cay the parasite Trichomonas Vaginalis releases a protein causing inflammation in the prostate that speeds up the growth of cancerous cells.

Chairman of Urology at Lenox Hill Hospital, Dr. David Samadi wrote another piece titled “Preventing & Understanding Prostatitis,” which is published on his prostate cancer 911 blog, and explains how bacterial infections and STDs can impact the prostate.Of particular concern is taking preventative measures to diminish risk, says Dr. Samadi, and if any symptoms are present, consulting an experienced doctor.Dr. David Samadi is considered an international authority on urologic diseases, with a specialty in prostate cancer. He is also an expert in male reproductive health. His clinical interests have been focused on laparoscopic and robotic surgery for nearly two decades. Dr. Samadi is a medical correspondent for Fox News, has a radio broadcast where he answers questions, and offers his professional advice, and is a medical expert on his weekend show, Sunday Housecall, which airs at 12:30p on Sundays.Don’t miss an opportunity to learn more about prostate health. Visit Dr. David Samadi’s blog and his Facebook page to keep up with the latest news and developments.

Clay Siegall single-handedly conjures antibody drug conjugates from the ether

In the world of cancer research, no name stands above the crowd quite like that of Clay Siegall. After having spent more than 15 years as a senior researcher at some of the largest pharmaceutical firms in the entire world, Dr. Siegall was able to finally branch out on his own, founding Seattle Genetics. This company has proven to be one of the most successful new biotech startups in the history of the biopharmaceutical space, having gone from nothing to one of the most important manufacturers of targeted cancer therapy drugs in the world.

The stunning trajectory of Dr. Siegall’s singular career can be traced back to his days at the National Cancer Institute. There, Dr. Siegall first became familiarized with a new class of cancer-fighting drugs known as targeted cancer therapies. This exciting new area of cancer research grabbed Dr. Siegall’s attention. The new kind of drug promised to virtually eliminate all known side effects associated with chemotherapy, some of which were so severe that they actually limited the amount of drugs that can be safely administered to patients who needed them the most.

After spending four years at the National Cancer Institute, to stand out research your Dr. Clay Siegall was eventually recruited by one of the largest pharmaceutical companies in the world. He eventually accepted the position at Bristol-Myers Squibb, heading up a team of researchers that was looking into new ways to create targeted cancer therapies.

It was at Bristol-Myers Squibb that Dr. Siegall first had an epiphany. He realizes that human antibodies that were so effective at seeking out malignant issues could be weaponized, binding to them highly lethal cytotoxins that could be effectively carried directly to the site of the tumor. This new method of delivery would be able to completely eliminate all systemic release of chemotherapeutic drugs into the system of the subject to which they were being administered. This could effectively eliminate all side effects associated with chemotherapy, thereby dramatically increasing the safe dosage that can be administered to patients, even those in the late stages of cancer.